<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002018'>Malignant tumors</z:mp> are a frequent complication in the late phase after organ transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are the second most <z:e sem="disease" ids="C1333132" disease_type="Neoplastic Process" abbrv="">common tumor</z:e>, exceeded only by cutaneous <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Compared to the general population, the organ transplant patients have a 30-60 fold increased risk of developing non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A 55-year-old, <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C-positive man developed an Epstein-Barr virus (EBV)- negative Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) first appearing on the gingiva under immunosuppressive therapy nine years after allogenic renal transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>He died 37 days after the <z:hpo ids='HP_0003674'>onset</z:hpo> of polychemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Immediately before his <z:hpo ids='HP_0011420'>death</z:hpo>, meningeal involvement by the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> was diagnosed </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> after organ transplantation is often found at extranodal sites; it involves the central <z:mp ids='MP_0008912'>nervous</z:mp> system more frequently than it does in immunocompetent patients </plain></SENT>
<SENT sid="7" pm="."><plain>In 70% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> occurring after organ transplantation, genes or gene products related to EBV can be demonstrated within the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>The EBV status of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> is of important prognostic significance: EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> occurring in organ transplant patients usually responds well to reduction or cessation of immunosuppressive therapy; in some cases permanent complete remissions can be achieved even without chemotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, patients with EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> have a very poor prognosis and hardly respond, even to aggressive chemotherapy protocols </plain></SENT>
</text></document>